Abel S - Search Results

1

Maraviroc: pharmacokinetics and drug interactions.

Abel S, Back DJ, Vourvahis M. Abel S, et al. Antivir Ther. 2009;14(5):607-18. Antivir Ther. 2009. PMID: 19704163 Review.

2

Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.

Abel S, Davis JD, Ridgway CE, Hamlin JC, Vourvahis M. Abel S, et al. Antivir Ther. 2009;14(6):831-7. doi: 10.3851/IMP1297. Antivir Ther. 2009. PMID: 19812445 Clinical Trial.

3

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.

Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):5-18. doi: 10.1111/j.1365-2125.2008.03130.x. Br J Clin Pharmacol. 2008. PMID: 18333861 Free PMC article. Clinical Trial.

4

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):38-46. doi: 10.1111/j.1365-2125.2008.03134.x. Br J Clin Pharmacol. 2008. PMID: 18333864 Free PMC article. Clinical Trial.

5

Azoles, allylamines and drug metabolism.

Back DJ, Tjia JF, Abel SM. Back DJ, et al. Among authors: abel sm. Br J Dermatol. 1992 Feb;126 Suppl 39:14-8. doi: 10.1111/j.1365-2133.1992.tb00003.x. Br J Dermatol. 1992. PMID: 1311943

6

Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.

Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):19-26. doi: 10.1111/j.1365-2125.2008.03132.x. Br J Clin Pharmacol. 2008. PMID: 18333862 Free PMC article. Clinical Trial.

7

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):27-37. doi: 10.1111/j.1365-2125.2008.03133.x. Br J Clin Pharmacol. 2008. PMID: 18333863 Free PMC article. Clinical Trial.

8

The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):47-53. doi: 10.1111/j.1365-2125.2008.03135.x. Br J Clin Pharmacol. 2008. PMID: 18333865 Free PMC article. Clinical Trial.

9

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.

Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK. Abel S, et al. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):60-7. doi: 10.1111/j.1365-2125.2008.03137.x. Br J Clin Pharmacol. 2008. PMID: 18333867 Free PMC article. Clinical Trial.

10

Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.

Rosario MC, Jacqmin P, Dorr P, James I, Jenkins TM, Abel S, van der Ryst E. Rosario MC, et al. Among authors: abel s. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):86-94. doi: 10.1111/j.1365-2125.2008.03140.x. Br J Clin Pharmacol. 2008. PMID: 18333870 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

781 results

Search Page

Filters